{"entity":{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of MCLA-129 and Ensartinib in advanced solid tumours, run by Betta Pharmaceuticals Co., Ltd., now recruiting.","summary":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07448116 by Betta Pharmaceuticals Co., Ltd., with 164 participants planned, started 2026-01-31 and due to reach its primary completion in 2029-02-01. Interventions recorded: MCLA-129 and Ensartinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07448116","url":"https://clinicaltrials.gov/study/NCT07448116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["mcla-129","ensartinib"],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07448116","phase":"1/2","setting":"A Multi-cohort, Open-label Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Combination With Ensartinib Hydrochloride in Patients With Advanced Solid Tumors.","sponsor":"Betta Pharmaceuticals Co., Ltd.","participation":[{"nct":"NCT07448116","source":"https://clinicaltrials.gov/study/NCT07448116","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"7b421f4b6889b298b4b4aaee97d85faad40fa6289a181ce0e4eb622131cc875f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-04","leadSponsor":"Betta Pharmaceuticals Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":164,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-31","startedType":"actual","enrolled":164,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07448116/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"},{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}]}}